15th October 2019 Content supplied by: Liofilchem s.r.l.
FDA-Cleared Liofilchem MTS™ (MIC Test Strip) Imipenem-Relebactam (I/R)
Liofilchem has received clearance from the FDA to market in the United States the Imipenem-relebactam 0.002/4-32/4 MTS™ (MIC Test Strip), a quantitative assay for determining the Minimum Inhibitory Concentration (MIC) of Imipenem-relebactam.
Imipenem-relebactam MTS™ has been shown to be active both clinically and in vitro against the following bacterial species: Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, Pseudomonas aeruginosa.
More technical details on the Imipenem-relebactam MIC Test Strip IFU Imipenem-relebactam MIC Test Strip IFU
MTS™ (MIC Test Strips) are porous strips with special features (International Patent) that are impregnated with a predefined concentration gradient of antibiotic, across 15 two-fold dilutions of a conventional MIC method. On one side of the strip there is a printed MIC scale in μg/mL and a code that identifies the antimicrobial agent.
MTS™ Imipenem-relebactam 0.002/4-32/4
- 10 strip pack: ref. 920761
- 30 strip pack: ref. 92076
- 100 strip pack: ref. 920760
The MTS™ range comprises antibiotics, antifungals, antimycobacterials, and combined strips for detection of resistance mechanisms (ESBL, MBL, KPC, AmpC and GRD) for over 150 items, each available in three pack formats (10, 30 and 100), for the widest gradient strip range in the international market.
Availability in USA:
Imipenem-relebactam is the most recent FDA approved item in the MTS™ (MIC Test Strip) product range, following approvals of Vancomycin, Dalbavancin, Ceftolozane-tazobactam, Meropenem, Ceftazidime, Telavancin, Tedizolid, Delafloxacin, Clindamycin, Erythromycin, Linezolid, Meropenem-vaborbactam, Azithromycin, Ceftazidime-avibactam, Plazomicin, Penicillin G , Eravacycline, Omadacycline, Tetracycline, Levofloxacin, Ciprofloxacin, Gentamicin and Doxycyclin strips. The rest of the MTS™ range is available in the United States as research use only devices.
Availability in Europe and rest of the world:
The entire MTS™ product catalog is CE marked and fully available as IVD for clinical diagnostics purposes in Europe.
The MTS™ range is also compliant to MDSAP (Australia TGA, Brazil ANVISA, Health Canada, USA FDA, Japan MHLW/PMDA) and is registered at the competent Authority in many countries outside Europe as a clinical diagnostic device.
Date Published: 15th October 2019
Source article link: https://www.liofilchem.com/